ImThera To Debut Neurostim Device For Sleep Apnea In 2010
This article was originally published in The Gray Sheet
Executive Summary
ImThera Medical will begin a clinical trial in November of its Aura6000 neurostimulation implant to treat obstructive sleep apnea, aiming for European marketing approval by the end of 2010
You may also be interested in...
Correction
Obstructive sleep apnea device developer ImThera clarifies that 40% of OSA patients have a moderate to severe form of the condition, and 85% to 90% of OSA is tongue-based (1"The Gray Sheet" Oct. 19, 2009)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”